Table 2.
Changes in total LBM in kilograms
| Longitudinal studies | |||||||
| Author (year) |
Participants (N) | Baseline mean±SD (95% CI) |
12 Months mean±SD (95% CI) |
12–31 months mean±SD |
% Change | P | T (nmol/L) Base-post GAHT |
| TW | |||||||
| Mueller et al (2011)11 | 84 | 59.6 (54.6–64.6) |
57.2 (54.0–64.1) |
−4.0 | <0.005 | 13.6–0.6 | |
| Wierckx et al (2014)45 | 40 (oral oestrogen) 12 (transdermal oestrogen) |
56.0±7.5 62.6±9.3 |
53±8 59.7±8.1 |
−5.4 −4.6 |
<0.001 <0.05 |
18.0–0.4 19.7–0.5 |
|
| Gava et al (2016)38 | 20 (cyproterone acetate) 20 (leuprolide acetate) |
51.7±8.3 50.2±7.0 |
49.9±7.8 49.8±6.7 |
−3.5 −0.8 |
>0.05 >0.05 |
16.3–0.7 22.2–0.7 |
|
| Auer et al (2018)40 | 45 | 59.5±8.7 (56.9–62.0) |
57.5±12 (53.9–60.2) |
−3.4 | <0.001 | 17.5–1.9 | |
| Klaver et al (2018)15 | 179 | 57.2±8.3 | 55.5 (54.9–56.1) |
−3.0 | <0.001 | ||
| Tack et al (2018)36 | 21 | 47.0±6.4 | 44.8±6.3 | −4.7 | <0.01 | 15.2–8.8 | |
| Haraldsen et al (2007)51 | 12 | 54.4±6.2 | 52.2 | −4.0 | <0.001 | 16.8–8.6 | |
| Van Caenegem et al (2015)41 | 49 | 57.4±8.7 | 55.1±8.7 | −4.0 | <0.001 | 19.0–0.5 | |
| Cross-sectional studies | ||||||||
| Author (year) |
Participants (N) | TW baseline mean±SD |
TW 48 months mean±SD |
CM mean±SD |
% Difference | P | T (nmol/L) TW |
|
| TW | CM | |||||||
| Lapauw et al (2008)54 | 23 | 46 | 51.2±8.4 | 61.8±7.9 | −17.2 | <0.001 | 1.1 | |
| Haraldsen et al (2007)51 | 12 | 77 | 54.4±6.2 | 59.1±5.7 | −8.0 | <0.05 | 16.8 | |
| Van Caenegem et al (2015)41 | 49 | 49 | 57.4±8.7 | 61.3±6.8 | −6.4 | <0.05 | 19.0 | |
Data are from dual energy X-ray absorptiometry scans.
CM, cismen; LBM, lean body mass; TW, transwomen.